• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

贝达喹啉的苯甲酸盐、盐酸盐、丙二酸盐和烟酸盐的合成、表征及稳定性评估

Synthesis, Characterization, and Stability Assessment for the Benzoate, Hydrochloride, Malonate, and Nicotinate Salts of Bedaquiline.

作者信息

Okezue Mercy A, Byrn Stephen R

机构信息

Industrial and Physical Pharmacy Department, Purdue University, West Lafayette, IN 47907, USA.

出版信息

Pharmaceuticals (Basel). 2023 Feb 8;16(2):257. doi: 10.3390/ph16020257.

DOI:10.3390/ph16020257
PMID:37259402
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9963305/
Abstract

Bedaquiline has been approved as a combination therapy to treat multi-drug-resistant tuberculosis in adults ≥ 18 years old. The citrate, fumarate, phosphate, and tartrate salts have obtained patents, but the structures for these moieties have not been extensively described in the literature; only the powder X-ray patterns have been published. To expand the knowledge of the bedaquiline structure, this study provides detailed information for the synthesis, elucidation, characterization, and stability of four additional new potential molecular entities, namely, benzoate, hydrochloride (HCl), nicotinate, and malonate salts. The salts were formed using a 1:1 ratio of the counter ions (acids) to a 30 mg equivalent of the bedaquiline free base. The principles of the International Conference on Harmonization Q6 were used to characterize the new salts and their stability-indicating parameters were evaluated at 0, 3, and 6 months under accelerated conditions of 40 °C and 75% relative humidity. The benzoate salt exhibited the lowest tendency to lose its chemical potency. Aside from the HCl salt, the others retained their chemical structure, displaying long-term stability. All salts were non-hygroscopic and the hydrated benzoate and nicotinate salts were stable to dehydration. Regarding their chemical potencies, thermal analysis, chemical stability, and water sorption potential, the salts were ranked as follows: benzoate > malonate > nicotinate > HCl.

摘要

贝达喹啉已被批准作为一种联合疗法,用于治疗18岁及以上成人的耐多药结核病。柠檬酸盐、富马酸盐、磷酸盐和酒石酸盐已获得专利,但这些部分的结构在文献中并未得到广泛描述;仅发表了粉末X射线图谱。为了扩展对贝达喹啉结构的认识,本研究提供了另外四种新的潜在分子实体,即苯甲酸盐、盐酸盐(HCl)、烟酸盐和丙二酸盐的合成、阐释、表征及稳定性的详细信息。这些盐是使用抗衡离子(酸)与30毫克当量的贝达喹啉游离碱按1:1的比例形成的。采用国际协调会议Q6的原则对新盐进行表征,并在40℃和75%相对湿度的加速条件下,于0、3和6个月时评估其稳定性指示参数。苯甲酸盐表现出最低的化学效力损失倾向。除盐酸盐外,其他盐均保持其化学结构,显示出长期稳定性。所有盐均不吸湿,水合苯甲酸盐和烟酸盐对脱水稳定。就其化学效力、热分析、化学稳定性和吸水潜力而言,这些盐的排序如下:苯甲酸盐>丙二酸盐>烟酸盐>盐酸盐。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8f7/9963305/41153ce0d3b3/pharmaceuticals-16-00257-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8f7/9963305/0b5e0f98b1bb/pharmaceuticals-16-00257-g0A1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8f7/9963305/e266728220fd/pharmaceuticals-16-00257-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8f7/9963305/9a99147c4d73/pharmaceuticals-16-00257-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8f7/9963305/eaa3524f6701/pharmaceuticals-16-00257-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8f7/9963305/2052ea647367/pharmaceuticals-16-00257-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8f7/9963305/5ddac2226f62/pharmaceuticals-16-00257-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8f7/9963305/66685f48d415/pharmaceuticals-16-00257-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8f7/9963305/6ee4e74323af/pharmaceuticals-16-00257-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8f7/9963305/55aececf6d9d/pharmaceuticals-16-00257-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8f7/9963305/cb49e64c3d27/pharmaceuticals-16-00257-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8f7/9963305/41153ce0d3b3/pharmaceuticals-16-00257-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8f7/9963305/0b5e0f98b1bb/pharmaceuticals-16-00257-g0A1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8f7/9963305/e266728220fd/pharmaceuticals-16-00257-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8f7/9963305/9a99147c4d73/pharmaceuticals-16-00257-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8f7/9963305/eaa3524f6701/pharmaceuticals-16-00257-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8f7/9963305/2052ea647367/pharmaceuticals-16-00257-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8f7/9963305/5ddac2226f62/pharmaceuticals-16-00257-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8f7/9963305/66685f48d415/pharmaceuticals-16-00257-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8f7/9963305/6ee4e74323af/pharmaceuticals-16-00257-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8f7/9963305/55aececf6d9d/pharmaceuticals-16-00257-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8f7/9963305/cb49e64c3d27/pharmaceuticals-16-00257-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8f7/9963305/41153ce0d3b3/pharmaceuticals-16-00257-g011.jpg

相似文献

1
Synthesis, Characterization, and Stability Assessment for the Benzoate, Hydrochloride, Malonate, and Nicotinate Salts of Bedaquiline.贝达喹啉的苯甲酸盐、盐酸盐、丙二酸盐和烟酸盐的合成、表征及稳定性评估
Pharmaceuticals (Basel). 2023 Feb 8;16(2):257. doi: 10.3390/ph16020257.
2
Determining the solubilities for benzoate, nicotinate, hydrochloride, and malonate salts of bedaquiline.测定苯甲酸盐、烟酸盐、盐酸盐和丙二酸盐的贝达喹啉的溶解度。
Int J Pharm. 2022 Nov 5;627:122229. doi: 10.1016/j.ijpharm.2022.122229. Epub 2022 Sep 23.
3
Salts and Polymorph Screens for Bedaquiline.贝达喹啉的盐类及多晶型筛选
AAPS PharmSciTech. 2021 Aug 25;22(7):228. doi: 10.1208/s12249-021-02106-7.
4
Crystal structures of salts of bedaquiline.贝达喹啉盐的晶体结构。
Acta Crystallogr C Struct Chem. 2020 Nov 1;76(Pt 11):1010-1023. doi: 10.1107/S2053229620013455. Epub 2020 Oct 19.
5
Fluoroquinolone salts with carboxylic acids.含羧酸的氟喹诺酮盐。
J Pharm Sci. 2011 Aug;100(8):3160-3176. doi: 10.1002/jps.22537. Epub 2011 Mar 10.
6
Pharmaceutical salts of ethionamide with GRAS counter ion donors to enhance the solubility.乙硫异烟胺与一般认为安全(GRAS)的抗衡离子供体形成的药用盐,以提高溶解度。
Eur J Pharm Sci. 2017 Jan 1;96:578-589. doi: 10.1016/j.ejps.2016.10.035. Epub 2016 Nov 1.
7
Comparison of pharmacokinetics and bioavailability of bedaquiline fumarate, benzoate and maleate in dogs.富马酸贝达喹啉、苯甲酸盐和马来酸盐在犬体内的药代动力学和生物利用度比较。
Int J Tuberc Lung Dis. 2023 Jan 1;27(1):28-33. doi: 10.5588/ijtld.22.0326.
8
Preparation, Characterization, and Selection of Optimal Forms of (S)-Carvedilol Salts for the Development of Extended-Release Formulation.(S)-卡维地洛盐的最优形式的制备、表征和选择,用于开发缓释制剂。
Mol Pharm. 2021 Jun 7;18(6):2298-2310. doi: 10.1021/acs.molpharmaceut.1c00100. Epub 2021 May 25.
9
Characterization of hydrochloride and tannate salts of diphenhydramine.苯海拉明盐酸盐和鞣酸盐的特性研究
Indian J Pharm Sci. 2008 Jul-Aug;70(4):482-6. doi: 10.4103/0250-474X.44598.
10
Preparation and characterization of dicarboxylic acids salt of aripiprazole with enhanced physicochemical properties.制备和表征具有增强的物理化学性质的阿立哌唑二酸盐。
Pharm Dev Technol. 2021 Apr;26(4):455-463. doi: 10.1080/10837450.2021.1888978. Epub 2021 Mar 3.

本文引用的文献

1
Determining the solubilities for benzoate, nicotinate, hydrochloride, and malonate salts of bedaquiline.测定苯甲酸盐、烟酸盐、盐酸盐和丙二酸盐的贝达喹啉的溶解度。
Int J Pharm. 2022 Nov 5;627:122229. doi: 10.1016/j.ijpharm.2022.122229. Epub 2022 Sep 23.
2
Salts and Polymorph Screens for Bedaquiline.贝达喹啉的盐类及多晶型筛选
AAPS PharmSciTech. 2021 Aug 25;22(7):228. doi: 10.1208/s12249-021-02106-7.
3
Maleate salts of bedaquiline.贝达喹啉的马来酸盐
Acta Crystallogr E Crystallogr Commun. 2021 Mar 26;77(Pt 4):433-445. doi: 10.1107/S2056989021002991. eCollection 2021 Apr 1.
4
Crystal structures of salts of bedaquiline.贝达喹啉盐的晶体结构。
Acta Crystallogr C Struct Chem. 2020 Nov 1;76(Pt 11):1010-1023. doi: 10.1107/S2053229620013455. Epub 2020 Oct 19.
5
New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid.耐多药结核病治疗的新进展:贝达喹啉和地拉曼德的临床应用
Infect Drug Resist. 2015 Oct 30;8:367-78. doi: 10.2147/IDR.S68351. eCollection 2015.
6
Salt Stability - The Effect of pHmax on Salt to Free Base Conversion.盐稳定性——最大pH值对盐向游离碱转化的影响。
Pharm Res. 2015 Sep;32(9):3110-8. doi: 10.1007/s11095-015-1691-5. Epub 2015 Apr 15.
7
Characterization of the "hygroscopic" properties of active pharmaceutical ingredients.活性药物成分“吸湿性”特性的表征
J Pharm Sci. 2008 Mar;97(3):1047-59. doi: 10.1002/jps.21033.
8
Salt formation to improve drug solubility.通过盐形成来提高药物溶解度。
Adv Drug Deliv Rev. 2007 Jul 30;59(7):603-16. doi: 10.1016/j.addr.2007.05.010. Epub 2007 May 29.
9
Pharmaceutical evaluation of early development candidates "the 100 mg-approach".早期研发候选药物的药学评估 “100毫克方法”
Int J Pharm. 2004 May 4;275(1-2):1-12. doi: 10.1016/j.ijpharm.2004.01.034.
10
General pharmaceutics--the new physical pharmacy.普通药剂学——新物理药学
J Pharm Sci. 2003 Jul;92(7):1331-42. doi: 10.1002/jps.10366.